-62%

est. 2Y upside i

HealthcareSeries C

Loyal is a clinical-stage veterinary medicine company developing drugs intended to extend the lifespan and healthspan of dogs. In other words, our mission is to help dogs live longer, healthier lives.

Rank

#2646

Sector

Biotechnology, Animal Health

Est. Liquidity

~3Y

Data Quality

Data: Medium

Loyal presents a moderate upside opportunity, driven by its pioneering position in canine longevity drugs and significant regulatory milestones, including FDA acceptance for effectiveness and safety for LOY-002.

Last updated: March 10, 2026

Bull (35%)+150%

Loyal achieves Expanded Conditional Approval (XCA) for LOY-002 and demonstrates strong initial market adoption, exceeding revenue expectations. This validates the canine longevity market, leading to a significant acquisition by a major animal health pharmaceutical company or a successful IPO at a valuation of $1.06B+, representing a 2.5x return on the current valuation.

Base (25%)+20%

LOY-002 receives XCA and launches, but market adoption is slower than anticipated, or further clinical data from the STAY study is mixed. The company makes steady progress but faces ongoing capital needs, leading to an exit at a modest premium to current valuation, around $510M, or a flat IPO, where common stock returns are limited due to the significant preference stack.

Bear (40%)-60%

LOY-002 faces unexpected safety concerns or significant regulatory delays, or the STAY study fails to demonstrate clear efficacy for full approval. This leads to a down round or a distressed acquisition at a valuation of $170M or less, effectively wiping out common stock value due to the $250M in liquidation preferences.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Funding Intensity

59%

Investors hold $250M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out, significantly impacting value in exits at or below the current $425M valuation.

Dilution Risk

high

As a clinical-stage company with high capital intensity, further funding rounds are highly likely before profitability or a liquidity event, leading to additional dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Loyal's equity.

Questions to Ask at the Interview

Strategic questions based on Loyal's data — designed to show you've done your homework.

  • 1

    “Given the significant regulatory lead Loyal has established with the FDA for lifespan extension drugs, how do you plan to leverage this advantage to accelerate market penetration and defend against potential future entrants from larger animal health incumbents like Zoetis or Elanco?”

  • 2

    “Loyal's business model relies on recurring monthly subscriptions for daily pills or periodic injections. What are the key strategies for driving initial veterinarian adoption and ensuring long-term pet owner adherence, especially considering the preventive nature of the drug for a non-symptomatic condition?”

  • 3

    “With over $250M raised and a $425M valuation, the investor preference stack is substantial. How does the company envision the path to a liquidity event (IPO or acquisition) that would provide meaningful returns for common stock holders, and what is the anticipated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -62% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.